A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Primary objective: To study the biological effectiveness of radium-223 therapy measured as: * Time to occurrence of skeletal-related events(SREs) * Change in bone-specific alkaline phosphatase (bone-ALP) levels Secondary objectives: To study the efficacy of radium-223 therapy in terms of: * Frequency of new SREs * Proportions of patients with an SRE * Proportions of patients with SRE at different time points * Changes of biochemical markers of bone turnover * Treatment response with regard to pain and analgesic use(termed "Palliative effect" in study protocol) * Quality of life assessment * Overall survival To study the safety of the repeated radium-223 regimen Total Enrollment:64 Study start: February 2004